Publication Date
1-1-2022
Journal
Annals of Gastroenterology
DOI
10.20524/aog.2022.0735
PMID
36061160
PMCID
PMC9399572
PubMedCentral® Posted Date
7-15-2022
PubMedCentral® Full Text Version
Post-Print
Published Open-Access
yes
Keywords
Cytomegalovirus, immune checkpoint inhibitor, immune-related adverse events, cancer
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs), used for the treatment of solid and hematologic malignancies, come with the risk of immune-related adverse events (irAEs). Opportunistic infections (e.g., cytomegalovirus [CMV]) mimic irAE symptoms and are understudied in this population. We aimed to describe the incidence, characteristics, treatment and outcomes of CMV infection in ICI-treated patients.
METHODS: We conducted a single-center retrospective review of all adult patients who were CMV-positive after ICI therapy between 06/2011 and 05/2020. A CMV-positive non-ICI cohort was matched to the ICI group based on age, sex and cancer type. Variables of interest were collected through electronic medical records.
RESULTS: The study population comprised 192 patients overall. CMV infection incidence was 7.7% in ICI patients and 12.9% in non-ICI patients (P
CONCLUSIONS: CMV infection occurred in about 7.7% of the ICI-treated cancer population. The infection can be disseminated in multiple organs and has a wide spectrum of clinical symptoms. ICI-treated patients with a hematologic malignancy had higher viral clearance and recurrence than those with solid tumors. In this study, CMV itself did not lead to high mortality in cancer patients. Further study is needed to investigate the role of CMV infection in patients' irAEs and cancer outcome.
Included in
Allergy and Immunology Commons, Digestive System Diseases Commons, Gastroenterology Commons, Medical Immunology Commons, Oncology Commons
Comments
Associated Data